共 50 条
- [41] Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myelomaBMC CANCER, 2016, 16Baertsch, Marc-AndreaSchlenzka, JanaMai, Elias K.Merz, MaximilianHillengass, JensRaab, Marc S.Hose, DirkWuchter, PatrickHo, Anthony D.Jauch, AnnaHielscher, ThomasKunz, ChristinaLuntz, SteffenKlein, StefanSchmidt-Wolf, Ingo G. H.Goerner, MartinSchmidt-Hieber, MartinReimer, PeterGraeven, UllrichFenk, RolandSalwender, HansScheid, ChristofNogai, AxelHaenel, MathiasLindemann, Hans W.Martin, HansNoppeney, RichardWeisel, KatjaGoldschmidt, Hartmut
- [42] A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Usmani, Saad ZafarSchjesvold, FredrikRocafiguera, Albert OriolKarlin, LionelRifkin, Robert M.Yimer, Habte AragawLeBlanc, RichardTakezako, NaokiMcCroskey, Robert DonaldSuzuki, KenshiCavo, MicheleFacon, ThierryJagannath, SundarLonial, SagarGhori, RaziFarooqui, Mohammed Z. H.Liao, JasonMarinello, PatriciaSan-Miguel, Jesus
- [43] Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trialJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (18)Jacobus, Susanna J.Cohen, Adam D.Weiss, MatthiasCallander, Natalie ScottSingh, Avina A.Parker, Terri L.Menter, Alex R.Yang, XuezhongParsons, Benjamin MarshallKumar, PankajKapoor, PrashantRosenberg, Aaron SethZonder, Jeffrey A.Faber, Edward AnthonyLonial, SagarRichardson, Paul G.Orlowski, Robert Z.Wagner, Lynne I.Rajkumar, S. Vincent
- [44] Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) TrialBLOOD, 2015, 126 (23)Avet-Loiseau, HerveHulin, CyrilleBenboubker, LoftiDimopoulos, Meletios A.Belch, AndrewReece, DonnaCatalano, JohnPinto, AntonioLudwig, HeinzBahlis, Nizar J.Cavo, MicheleAttal, MichelMoreau, PhilippeQiu, LuguiLeBlanc, RichardSchots, RikRajkumar, S. VincentMarek, JenniferChen, GuangYiu, WaiErvin-Haynes, AnnetteFacon, Thierry
- [45] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialLANCET ONCOLOGY, 2013, 14 (11): : 1055 - 1066San Miguel, JesusWeisel, KatjaMoreau, PhilippeLacy, MarthaSong, KevinDelforge, MichelKarlin, LionelGoldschmidt, HartmutBanos, AnneOriol, AlbertAlegre, AdrianChen, ChristineCavo, MicheleGarderet, LaurentIvanova, ValentinaMartinez-Lopez, JoaquinBelch, AndrewPalumbo, AntonioSchey, StephenSonneveld, PieterYu, XinSternas, LarsJacques, ChristianZaki, MohamedDimopoulos, Meletios
- [46] PX-171-006, A PHASE IB DOSE-ESCALATION STUDY OF CARFILZOMIB plus LENALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMAHAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 157 - 157Wang, M.Bensinger, W.Orlowski, R.Alsina, M.Martin, T.Singhal, S.Gabrail, N.Vallone, M.Kauffman, M.Niesvizky, R.
- [47] THE FIRST TRIAL: ANALYSIS OF THE ASIAN SUBGROUP OF TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH CONTINUOUS LENALIDOMIDE AND LOW-DOSE DEXAMETHASONEHAEMATOLOGICA, 2016, 101 : 548 - 549Lu, J.Lee, J. H.Huang, S. Y.Qiu, L.Lee, J. J.Liu, T.Yoon, S. S.Kim, K.Shen, Z. X.Eom, H. S.Chen, W. M.Min, C. K.Kim, H. J.Lee, J. O.Kwak, J. Y.Yiu, W.Chen, G.Ervin-Haynes, A.Hulin, C.Facon, T.
- [48] Sustained Improvement in HealthRelated Quality of Life in TransplantIneligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA TrialBLOOD, 2021, 138Perrot, AuroreFacon, ThierryKumar, ShajiPlesner, TorbenOrlowski, Robert Z.Moreau, PhilippeBahlis, Nizar J.Basu, SupratikNahi, HarethHulin, CyrilleQuach, HangGoldschmidt, HartmutO'Dwyer, Michael E.Venner, Chris P.Weisel, KatjaMace, Joseph R.Raje, Noopur S.Tiab, MouradMacro, MagaretFrenzel, LaurentLeleu, XavierLiu, KevinFastenau, JohnGries, Katharine S.Ho, Kai FaiMistry, PankajTromp, BrendaDelioukina, MariaVermeulen, JessicaUsmani, Saad Z.
- [49] A FRAILTY SCALE PREDICTS OUTCOMES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH CONTINUOUS LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN THE FIRST (MM-020) TRIALHAEMATOLOGICA, 2016, 101 : 258 - 259Facon, T.Hulin, C.Dimopoulos, M. A.Belch, A.Meuleman, N.Mohty, M.Chen, W. M.Kim, K.Zamagni, E.Rodriguez-Otero, P.Renwick, W.Rose, C.Tempescul, A.Boyle, E.Palumbo, A.Guo, S.Monzini, M. S.Sturniolo, M.Ervin-Haynes, A.Fermand, J. P.
- [50] Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trialLANCET ONCOLOGY, 2021, 22 (11): : 1582 - 1596Facon, ThierryKumar, Shaji K.Plesner, TorbenOrlowski, Robert Z.Moreau, PhilippeBahlis, NizarBasu, SupratikNahi, HarethHulin, CyrilleQuach, HangGoldschmidt, HartmutO'Dwyer, MichaelPerrot, AuroreVenner, Christopher P.Weisel, KatjaMace, Joseph R.Raje, NoopurTiab, MouradMacro, MargaretFrenzel, LaurentLeleu, XavierAhmadi, TahamtanWang, JianpingVan Rampelbergh, RianUhlar, Clarissa M.Tromp, BrendaDelioukina, MariaVermeulen, JessicaUsmani, Saad Z.